Trial
NCT04631744
Cabozantinib in Patients With Metastatic Castrate Resistant Prostate Cancer (mCRPC)
Phase IITERMINATEDOPERATIONALConfidence: HIGH
Sponsor
Weill Medical College of Cornell University
Collaborators
Exelixis
Condition
Prostate Cancer
Intervention
Cabozantinib
Why stopped
Low accrual
Provenance
Dataset: 2026-07-02 • Source: ClinicalTrials.gov API v2 • Last update: 2026-05-01